原发性与继发性乳腺弥漫性大B细胞淋巴瘤临床特征比较：横滨血液学合作研究组多中心回顾性研究
Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study.
作者信息
Takahashi Hiroyuki, Sakai Rika, Sakuma Takayuki, Matsumura Ayako, Miyashita Kazuho, Ishii Yoshimi, Nakajima Yuki, Numata Ayumi, Hattori Yukako, Miyazaki Takuya, Hashimoto Chizuko, Koharazawa Hideyuki, Takemura Sachiya, Taguchi Jun, Fujimaki Katsumichi, Fujita Hiroyuki, Nakajima Hideaki
机构信息
Department of Hematology and Medical Oncology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ward, Yokohama, 241-8515 Kanagawa Japan.
Department of Hematology, Yokohama City University Medical Center, Yokohama, Kanagawa Japan.
出版信息
Indian J Hematol Blood Transfus. 2021 Jan;37(1):60-66. doi: 10.1007/s12288-020-01307-7. Epub 2020 Jun 23.
We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL ( = 11), limited stage SBL (LSBL; = 6), and advanced stage SBL (ASBL, = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group ( = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS ( = 0.01) and PFS ( = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL.
我们对累及乳腺的弥漫性大B细胞淋巴瘤（DLBCL）进行了回顾性分析，以比较原发性乳腺淋巴瘤（PBL）与继发性乳腺淋巴瘤（SBL；尤其是局限期病例）的预后。我们回顾性分析了2000年1月至2012年8月期间接受化疗的25例累及乳腺的弥漫性大B细胞淋巴瘤（DLBCL）患者的记录。我们比较了原发性乳腺淋巴瘤（PBL，n = 11）、局限期继发性乳腺淋巴瘤（LSBL，n = 6）和晚期继发性乳腺淋巴瘤（ASBL，n = 8）患者的临床特征和预后。与继发性乳腺淋巴瘤组相比，原发性乳腺淋巴瘤组中乳腺肿瘤（BT）>5 cm的患者明显更少（P = 0.02）。中位随访71.3个月后，我们观察到原发性乳腺淋巴瘤组的5年总生存率（OS）（90.0%）明显优于局限期继发性乳腺淋巴瘤组（33.3%，P = 0.01），但无进展生存期（PFS）并非如此。乳腺肿瘤>5 cm的患者的总生存率（P = 0.01）和无进展生存期（PFS，P = 0.04）均比乳腺肿瘤≤5 cm的患者差。在局限期DLBCL中，原发性乳腺淋巴瘤的预后优于继发性乳腺淋巴瘤。
Zotero 插件